Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Lee, Dasom ^{[1
]}

Kambhampati, Swetha ^{[2
]}

Bobillo, Maria Silvina Odstrcil ^{[3
]}

Adedokun, Babatunde ^{[4
]}

Shadman, Mazyar ^{[5
,6
]}

Olson, Amanda L. ^{[7
]}

Herrera, Alex F. ^{[8
]}

Lee, Catherine J. ^{[5
,6
]}

Jacobson, Caron A. ^{[9
]}

Bye, Matthew ^{[10
]}

Hamadani, Mehdi ^{[10
]}

Kim, Soyoung ^{[11
]}

Dahiya, Saurabh ^{[12
]}

Hu, Zhen-Huan ^{[4
]}

Speth, Kelly ^{[4
]}

To, Christina ^{[4
]}

Mirjah, Debbie L. ^{[13
]}

Best, Timothy ^{[4
]}

Locke, Frederick L. ^{[14
]}

Ahmed, Nausheen ^{[15
]}

Tees, Michael T. ^{[16
]}

Pasquini, Marcelo C. ^{[17
]}

Ahmed, Sairah ^{[18
]}

机构：

[1] Stanford Univ, Div Hematol, Palo Alto, CA USA

[2] City Hope Natl Med Ctr, Yorba Linda, CA USA

[3] Univ Utah, Salt Lake City, UT USA

[4] Kite A Gilead Co, Santa Monica, CA USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Med Oncol Div, Seattle, WA USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI USA

[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Registry CIBMTR, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA

[12] Stanford Univ, Div Hematol, Stanford, CA USA

[13] Gilead Co, Santa Monica, CA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplant & Cellular Immunotherapy, Tampa, FL USA

[15] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA

[16] Sarah Cannon transplant & Cellular Therapy Network, Nashville, TN USA

[17] Dana Farber Canc Inst, Boston, MA USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：527 / 528

页数：2

共 50 条

[41] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
[42] Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
Ghobadi, Armin
Munoz, Javier
Westin, Jason
Locke, Frederick L.
Miklos, David B.
Rapoport, Aaron P.
Perales, Miguel-Angel
Reagan, Patrick M.
McGuirk, Joseph P.
Jacobson, Caron A.
Kersten, Marie Jose
Avivi, Irit
Peng, Andrew
Schupp, Marco
To, Christina
Oluwole, Olalekan O.
BLOOD, 2022, 140 : 1595 - 1597
[43] Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Vose, Julie M.
Lin, Yi
Budde, Lihua E.
Maloney, David G.
Jaglowski, Samantha
Riedell, Peter A.
Lekakis, Lazaros J.
Perales, Miguel-Angel
Kim, Jenny J.
Kawashima, Jun
Yang, Yin
Rossi, John M.
Goyal, Lovely
Neelapu, Sattva S.
BLOOD, 2020, 136
[44] Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L.
Miklos, D. B.
Jacobson, C. A.
Perales, M-A
Kersten, M-J
Oluwole, O. O.
Ghobadi, A.
Rapoport, A. P.
McGuirk, J.
Pagel, J. M.
Munoz, J.
Farooq, U.
van Meerten, T.
Reagan, P. M.
Sureda, A.
Flinn, I. W.
Vandenberghe, P.
Song, K. W.
Dickinson, M.
Minnema, M. C.
Riedell, P. A.
Leslie, L. A.
Chaganti, S.
Yang, Y.
Filosto, S.
Shah, J.
Schupp, M.
To, C.
Cheng, P.
Gordon, L., I
Westin, J. R.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07): : 640 - 654
[45] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Oluwole, Olalekan O.
Forcade, Edouard
Muñoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John M.
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Kim, Jenny J.
Zheng, Yan
Shen, Rhine R.
Vardhanabhuti, Saran
Van Meerten, Tom
BLOOD, 2021, 138
[46] Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
Fox, Christopher P.
Townsend, William
Gribben, John G.
Menne, Tobias
Kalakonda, Nagesh
Williams, Paula
Toron, Farah
Tyas, Emma
Cooper, Miranda
Rickards, Joshua
Radford, John
EJHAEM, 2024, 5 (05): : 992 - 997
[47] Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison
Neelapu, Sattva Swarup
Maloney, David G.
Salles, Gilles A.
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
Strati, Paolo
Leslie, Lori Ann
Shiraz, Parveen
Budde, L. Elizabeth
Oluwole, Olalekan O.
Ulrickson, Matthew
Ramakrishnan, Aravind
Sun, Jennifer
Shen, Rhine
Kanska, Justyna
McCroskery, Peter
Dong, Jinghui
Schupp, Marco Andreas
Xu, Hairong
Patel, Krish
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Nastoupil, Loretta J.
Jain, Michael D.
Spiegel, Jay Y.
Ghobadi, Armin
Lin, Yi
Dahiya, Saurabh
Lunning, Matthew A.
Lekakis, Lazaros J.
Reagan, Patrick M.
Oluwole, Olalekan O.
McGuirk, Joseph P.
Deol, Abhinav
Sehgal, Alison R.
Goy, Andre
Hill, Brian T.
Andreadis, Charalambos
Munoz, Javier
Westin, Jason R.
Chavez, Julio C.
Cashen, Amanda F.
Bennani, Nora N.
Rapoport, Aaron P.
Vose, Julie M.
Miklos, David B.
Neelapu, Sattva S.
Locke, Frederick L.
BLOOD, 2018, 132
[50] ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Chavez, Julio C.
Lin, Yi
Munoz, Javier
Ujjani, Chaitra Shankar
Riedell, Peter
De Vos, Sven
Oluwole, Olalekan O.
Kekre, Natasha
Yang, Yin
Goyal, Lovely
Backhouse, Kate
Milletti, Francesca
Kawashima, Jun
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →